SCHEDULE 13D/A: Fortress Biotech Solidifies Majority Voting Control in Mustang Bio with Increased Equity Stake

Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 12.4% of common stock, primarily through equity grants and preferred stock, solidifying its majority voting control.

Summary

• Fortress Biotech, Inc. (the "Reporting Person") has increased its beneficial ownership in Mustang Bio, Inc. (the "Issuer") to 6,569,450 shares of common stock, representing 12.4% of the Issuer's outstanding common stock.
• This increase is primarily due to the issuance of 530,899 shares of the Issuer's common stock as Offering Equity Grants and 3,452,345 shares of the Issuer's common stock as an Annual Equity Grant.
• Fortress Biotech holds all 250,000 outstanding shares of Mustang Bio's Class A preferred stock, which are convertible into 16,666 shares of common stock.
• Each share of Class A preferred stock is entitled to vote a number of shares equal to 1.1 times a fraction, ensuring the Class A preferred stock always constitutes a voting majority.
• The Reporting Person has sole voting power over all 6,569,450 beneficially owned shares.
• The beneficial ownership calculation is based on 48,768,763 shares of the Issuer's common stock reported outstanding as of December 6, 2024, plus other convertible securities and equity grants.
• Fortress Biotech also holds warrants for 66,666 shares of Mustang Bio common stock, exercisable until July 15, 2035, at an exercise price of $2.205 per share. These warrants were issued to Lindsay A. Rosenwald, M.D., and Michael S. Weiss, key executives of Fortress Biotech.

Sentiment

Score: 6

Explanation: The document is primarily factual and neutral, detailing changes in beneficial ownership based on pre-existing agreements. The increased stake by Fortress Biotech and its maintained voting control could be seen as a positive for stability and strategic alignment, but the ongoing dilution for common shareholders due to equity grants is a negative. The overall sentiment is slightly positive due to the implied commitment from a major shareholder, balanced by the dilution aspect.

Positives

• Increased beneficial ownership by Fortress Biotech may signal continued strategic alignment and commitment to Mustang Bio's long-term success.
• Fortress Biotech's Class A preferred stock ensures a stable voting majority, potentially providing consistent strategic direction for Mustang Bio.

Negatives

• The Class A preferred stock structure grants Fortress Biotech a perpetual voting majority, which significantly dilutes the voting influence of common shareholders.
• Ongoing equity grants to Fortress Biotech, including annual grants (2.5% of fully-diluted outstanding equity) and equity fees from financings (2.5% of gross amount), will result in continuous dilution for existing common shareholders.

Risks

• Control Risk: The Class A preferred stock structure ensures Fortress Biotech maintains a voting majority, which could limit the influence of other common shareholders on corporate governance and strategic decisions.
• Dilution Risk: Ongoing equity grants to Fortress Biotech (Annual Equity Grant and Offering Equity Grant) will lead to continuous dilution of common shareholders' equity.

Future Outlook

The document outlines ongoing equity grants to Fortress Biotech, including annual grants and grants tied to future equity or debt financings, indicating a continued increase in Fortress Biotech's ownership and control over Mustang Bio's capitalization.

Industry Context

This Schedule 13D/A filing primarily details changes in beneficial ownership and corporate control mechanisms within Mustang Bio, Inc., rather than broader industry trends. It highlights a common strategy in the biotechnology sector where a founding or major investor maintains significant control through special share classes and ongoing equity arrangements, which can influence strategic direction and capital allocation within the company.

Corporate Governance

Related Party Transactions

• Second Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Mustang Bio, Inc., which dictates equity fees for financings and annual equity grants to Fortress Biotech.
• Issuance of Common Stock Warrants by Fortress Biotech to Lindsay A. Rosenwald, M.D. (Chairman, President and CEO of Fortress Biotech) and Michael S. Weiss (Executive Vice Chairman, Strategic Development of Fortress Biotech and Chairman/Executive Chairman of Mustang Bio's Board of Directors).
• Fortress Biotech's ownership of all outstanding Class A preferred stock of Mustang Bio, which grants it a voting majority and receives PIK Dividends.

Stakeholder Impact

• Shareholders (Common): Experience ongoing dilution due to annual equity grants and equity fees from financings. Their voting power is significantly diminished due to Fortress Biotech's perpetual voting majority through Class A preferred stock.
• Fortress Biotech (as a shareholder): Benefits from increased ownership, continuous equity grants, and guaranteed voting control, solidifying its strategic influence over Mustang Bio.

Next Steps

• Fortress Biotech will continue to receive annual equity grants (2.5% of fully-diluted outstanding equity) and equity fees (2.5% of gross amount) from any future equity or debt financings by Mustang Bio, as per the Founders Agreement and Charter.
• PIK Dividends on Class A preferred stock will be issued annually on January 1 until conversion or redemption.

Key Dates

Recommendation

Keywords

Mustang Bio, Fortress Biotech, Schedule 13D/A, Beneficial Ownership, Common Stock, Preferred Stock, Equity Grants, Voting Control, SEC Filing, Biotechnology, Pharmaceuticals, Corporate Governance, Dilution